Patheon Closes Acquisition of IRIX Pharmaceuticals
DURHAM, NC--(Marketwired - April 01, 2015) - Patheon, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, has closed the previously announced transaction to acquire IRIX Pharmaceuticals, a Florence, S.C.-headquartered company that specializes in making difficult to manufacture Active Pharmaceutical Ingredients (API) for drugs from early and late development, through commercial launch. With the acquisition, Patheon establishes a North American presence for comprehensive API development and manufacturing to address customers' most challenging needs for drugs in all development phases.
Patheon, a business unit of DPx Holdings B.V., delivers a combination of unrivaled quality, reliability and compliance, with a reputation for scientific and technical excellence to customers in the pharmaceutical and biopharma sector. A leading global provider with more than 8,000 employees worldwide, Patheon has a comprehensive set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. For more information, visit http://www.patheon.com.